Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases

Oncology Letters

Volumn 11, Issue 1, 2016, Pages 689-692

  Jiang, Huifang ^a   Wu, Zhonglin ^b   Ren, Li ^a   Tao, Diehong ^a   Tong, Hongyan ^c  

^a TONGDE HOSPITAL OF ZHEJIANG PROVINCE   (China)

^b ZHEJIANG CHINESE MEDICAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY   (China)

Author keywords

Atypical chronic myeloid leukemia; Decitabine; Diagnosis; Myelodysplastic myeloproliferative neoplasms; Treatment

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD11B ANTIGEN; CD15 ANTIGEN; CD19 ANTIGEN; CD33 ANTIGEN; CD56 ANTIGEN; CD64 ANTIGEN; COMPLEMENT COMPONENT C3B RECEPTOR; DECITABINE; MICROSOMAL AMINOPEPTIDASE; T6 ANTIGEN;

ADULT; AGED; ANEMIA; ARTICLE; ATYPICAL CHRONIC MYELOID LEUKEMIA; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER FATIGUE; CANCER REGRESSION; CASE REPORT; COUGHING; DIZZINESS; DRUG EFFICACY; DYSPNEA; FLOW CYTOMETRY; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN TISSUE; HYPERPLASIA; LEUKOCYTE DIFFERENTIAL COUNT; MALE; MIDDLE AGED; MYELOBLAST; PROMYELOCYTE; PROTEIN EXPRESSION; THROMBOCYTE COUNT;

EID: 84948761396     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2015.3977     Document Type: Article

References (20)

1. Swerdlow SH, Campo E, Harris NL, et al: Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th edition. Swerdlow SH and Harris NL (eds). IARC Press, Lyon, France, pp 80-81, 2008.
2. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick H, Sultan C and Cox C: The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol 87: 746-754, 1994.
3. Galton DA: Haematological differences between chronic granulocytic leukaemia, atypical chronic myeloid leukaemia, and chronic myelomonocytic leukaemia. Leuk Lymphoma 7: 343-350, 1992.
4. Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F and Alimena G: Identification of risk factors in atypical chronic myeloid leukemia. Haematologica 91: 1566-1568, 2006.
5. Cannella L, Breccia M, Latagliata R, Frustaci A and Alimena G: Clinical and prognostic features of patients with myelodysplastic/myeloproliferative syndrome categorized as unclassified (MDS/MPD-U) by WHO classification. Leuk Res 32: 514-516, 2008.
6. Broseus J, Alpermann T, Wulfert M, et al; MPN and MPNr-EuroNet (COST Action BM0902): Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia 27: 1826-1831, 2013.
7. Wang SA, Hasserjian RP, Fox PS, Rogers HJ, Geyer JT, Chabot-Richards D, Weinzierl E, Hatem J, Jaso J, Kanagal-Shamanna R, et al: Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. Blood 123: 2645-2651, 2014.
8. Sutherland DR, Nayyar R, Acton E, Giftakis A, Dean S and Mosiman VL: Comparison of two single-platform ISHAGE-based CD34 enumeration protocols on BD FACSCalibur and FACSCanto flow cytometers. Cytotherapy 11: 595-605, 2009.
9. Piazza R, Valletta S, Winkelmann N, et al: Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nature Genetics 45: 18-24, 2013.
10. Oscier DG: Atypical chronic myeloid leukaemia, a distinct clinical entity related to the myelodysplastic syndrome? Br J Haematol 92: 582-586, 1996.
11. Jaffe ES, Harrris NL, Stein H, et al: Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. World Health Organization Classfication of Tumours. IARC Press, Lyon, France, 2001.
12. Hernández JM, del Cañizo MC, Cuneo A, et al: Clinical, hematological and cytogenetic characteristics of atypical chronic myeloid leukemia. Ann Oncol 11: 441-444, 2000.
13. Malcovati L and Cazzola M: Myelodysplastic/myeloproliferative disorders. Haematologica 93: 4-6, 2008.
14. Pabst T, Mueller BU, Zhang P, et al: Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet 27: 263-270, 2001.
15. Montefusco E, Alimena G, Lo Coco F, et al: Ph-negative and bcr-negative atypical chronic myelogenous leukemia: biological features and clinical outcome. Ann Hematol 65: 17-21, 1992.
16. Koldehoff M, Beelen DW, Trenschel R, et al: Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia. Bone Marrow Transplant 34: 1047-1050, 2004.
17. Issa JP and Kantarjian HM: Introduction: emerging role of epigenetic therapy: focus on decitabine. Semin Hematol 42 (3 Suppl 2): S1-S2, 2005.
18. Kantarjian H, O'Brien S, Giles F, et al: Decitabine low-dose schedule (100 mg/m2/course) in myelodysplastic syndrome (MDS). Comparison of three different dose schedules. Blood 106: 708, 2005.
19. Cashen A, Shah A, Helget A, Todt L, Fisher N and DiPersio J: A phase I pharmacokinetic trial of decitabine administered as a 3-hour infusion to patients with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS). Blood 106: 527-528, 2005.
20. Liu YL, Emanuel PD and Castleberry RP: Decitabine, a potential targeted therapeutic for juvenile myelomonocytic leukemia. Blood 106: 706, 2005.